

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and these are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

abaloparatide	Treatment of osteoporosis in postmenopausal women at increased risk of fracture.	Routinely available in line with national guidance	18/08/2025
Eladynos®			
SMC2764			
alectinib	Monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.	Routinely available in line with local or regional guidance	18/08/2025
Alecensa®			
SMC2749			
amivantamab	In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Not routinely available as not recommended for use in NHSScotland	18/08/2025
Rybrevent®			
SMC2758			
axicabtagene ciloleucel	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
Yescarta®			
SMC2695			
bevacizumab gamma	In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative	18/08/2025
Lytenava			
SMC2744			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
brentuximab vedotin Adcetris® SMC2762	Adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
dupilumab Dupixent® SMC2801	In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.	Not routinely available as not recommended for use in NHSScotland	18/08/2025
eplontersen Wainzua® SMC2755	Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/12/2025	18/08/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
etranacogene dezaparvovec Hemgenix® SMC2649	0 treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Routinely available in line with national guidance	18/08/2025
exagamglogene autotemcel Casgevy® SMC2709	0 Treatment of transfusion-dependent beta-thalassemia in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Routinely available in line with national guidance	18/08/2025
fezolinetant Veoza® SMC2798	0 Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHSScotland	18/08/2025
futibatinib Lytgobi® SMC2661	0 Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Iecanemab Leqembi® SMC2811	0 Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHSScotland	18/08/2025
Ietermovir Prevymis® SMC2853	0 Prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].	Not routinely available as not recommended for use in NHSScotland	18/08/2025
linzagolix Yselty® SMC2631	0 Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Routinely available in line with local or regional guidance	18/08/2025
mavacamten Camzyos® SMC2618	0 Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Routinely available in line with national guidance	18/08/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
mirikizumab Omvo® SMC2822	Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Routinely available in line with local or regional guidance	18/08/2025
Nivolumab, ipilimumab NCMAG121	Nivolumab in combination with ipilimumab for the neoadjuvant treatment of resectable stage III melanoma	Routinely available in line with local or regional guidance	18/08/2025
osimertinib Tagrisso® SMC2736	In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
pegunigalsidase alfa Elfabrio® SMC2665	for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Routinely available in line with national guidance	18/08/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
pembrolizumab	For the neoadjuvant treatment of stage IIIB to IIID or oligometastatic resectable stage IV melanoma	Routinely available in line with local or regional guidance	18/08/2025
NCMAG122			
pembrolizumab	In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
Keytruda®			
SMC2767			
ripretinib	Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
Qinlock®			
SMC2821			
selpercatinib	Monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).	Routinely available in line with local or regional guidance	18/08/2025
Retsevmo®			
SMC2732		18/08/2025	

Medicine	Condition being treated	NHSGGC Decision	Date of decision
selpercatinib Retsevmo® SMC2733	0 Monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).	Routinely available in line with local or regional guidance	18/08/2025
Semaglutide Wegovy SMC2497	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of <ul style="list-style-type: none"> • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity. 	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025
sodium thiosulfate Pedmarqsi® SMC2730	0 Prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours.	Routinely available in line with local or regional guidance	18/08/2025
tirzepatide Mounjaro® SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
trastuzumab deruxtecan Enhertu® SMC2854	Treatment of adult patients with unresectable or 0 metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options	Not routinely available as not recommended for use in NHSScotland	18/08/2025
zanubrutinib Brukinsa® SMC2819	Monotherapy for the treatment of adult patients 0 with mantle cell lymphoma (MCL) who have received at least one prior therapy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 06/10/2025	18/08/2025